Sign In
Buy AMGN
$360.45
-2.94 (-0.81%)
At Close: Jul 13, 2026
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Monday, 13'th Jul 2026
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AMGN DCF Analysis: Intrinsic Value $292 vs Price $363
07:30am, Monday, 13'th Jul 2026
On July 13, 2026, we present a detailed DCF analysis for Amgen Inc (AMGN), a company that has shown significant price performance over the past year with a 24.6
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
11:35am, Thursday, 09'th Jul 2026
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
How Safe Is Amgen's Dividend?
02:45pm, Tuesday, 07'th Jul 2026
Near-term headwinds could sink the stock, but there is more to the story.
Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”
12:30pm, Tuesday, 07'th Jul 2026
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
07:01pm, Monday, 06'th Jul 2026
Amgen (AMGN) closed the most recent trading day at $366.44, moving 2.06% from the previous trading session.
The Dow Couldn't Keep Up With Chip Stocks on Monday
02:29pm, Monday, 06'th Jul 2026
Broadcom's Apple deal and AMD's self-driving ambitions powered the Nasdaq higher on Monday while the Dow spun its wheels.
Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Monday, 06'th Jul 2026
Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel
04:47pm, Wednesday, 01'st Jul 2026
A federal judge on Wednesday blocked Colorado from capping the price of Amgen's blockbuster arthritis drug Enbrel, a first-of-its-kind move by a U.S. state.
Amgen or Biogen: Which Biotech Stock Appears Better Poised?
10:05am, Wednesday, 01'st Jul 2026
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
09:16am, Wednesday, 01'st Jul 2026
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
10:01am, Tuesday, 30'th Jun 2026
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Alphabet Just Joined the Dow Jones Industrial Average. 3 Dow Dividend Stocks to Buy Now.
06:05am, Tuesday, 30'th Jun 2026
Cisco Systems is on a roll with its AI-powered platform. Coca-Cola saw volume growth in each of its marketing segments in the first quarter.
Medical journal retracts paper on Amgen's Tavneos drug trial after FDA findings
04:46pm, Monday, 29'th Jun 2026
The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen's rare-disease drug, citing concerns that patient outcome data were a
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
09:24am, Monday, 29'th Jun 2026
The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN) new thyroid eye disease (TED) treatment, Lumvoa (veligrotug-vvze).
